Non-steroidal anti-inflammatory drugs and the risk of a second hip fracture: A propensity-score matching study

BMC Musculoskeletal Disorders

Volumn 17, Issue 1, 2016, Pages

  Chuang, Po Yao ^a,b   Shen, Shih Hsun ^a,b   Yang, Tien Yu ^a,b   Huang, Tsan Wen ^a,b   Huang, Kuo Chin ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Fragility hip fracture; Non steroidal anti inflammatory drugs; Population based study; Propensity score matching; Second hip fracture

Indexed keywords

ACETYLSALICYLIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CELECOXIB; DEXAMETHASONE; DICLOFENAC; ETODOLAC; IBUPROFEN; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; ROFECOXIB;

AGE; ARTICLE; COMORBIDITY; CONTROLLED STUDY; CORRELATIONAL STUDY; DOSE RESPONSE; DRUG EXPOSURE; FOLLOW UP; HIP FRACTURE; HUMAN; LONGITUDINAL STUDY; PROPENSITY SCORE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SURVIVAL ANALYSIS; TREATMENT DURATION; TREND STUDY; AGED; CASE CONTROL STUDY; CHEMICALLY INDUCED; FACTUAL DATABASE; FEMALE; HEALTH SURVEY; MALE; RECURRENT DISEASE; TAIWAN;

ACETAMINOPHEN; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; DATABASES, FACTUAL; DICLOFENAC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HIP FRACTURES; HUMANS; MALE; POPULATION SURVEILLANCE; PROPENSITY SCORE; RECURRENCE; RISK FACTORS; TAIWAN;

EID: 84978998650     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/s12891-016-1047-2     Document Type: Article

References (31)

1. Kanis JA, Odén A, McCloskey EV, Johansson H, Wahl DA, Cooper C. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int. 2012;23(9):2239-56.
2. Ryg J, Rejnmark L, Overgaard S, Brixen K, Vestergaard P. Hip fracture patients at risk of second hip fracture: a nationwide population-based cohort study of 169,145 cases during 1977-2001. J Bone Miner Res. 2009;24(7):1299-307.
3. Shen SH, Huang KC, Tsai YH, et al. Risk analysis for second hip fracture in patients after hip fracture surgery: a nationwide population-based study. J Am Med Dir Assoc. 2014;15(10):725-31.
4. Lönnroos E, Kautiainen H, Karppi P, Hartikainen S, Kiviranta I, Sulkava R. Incidence of second hip fractures. A population-based study. Osteoporos Int. 2007;18(9):1279-85.
5. Khosla S, Amin S, Orwoll E. Osteoporosis in men. Endocr Rev. 2008;29(4):441-64.
6. Pietschmann P, Rauner M, Sipos W, Kerschan-Schindl K. Osteoporosis: an age-related and gender-specific disease - a mini-review. Gerontology. 2009;55(1):3-12.
7. Vestergaard P, Rejnmark L, Mosekilde L. Hip fracture prevention: Cost-effective strategies. Pharmacoeconomics. 2001;19(5 Pt 1):449-68.
8. Raisz LG. Potential impact of selective cyclooxygenase-2 inhibitors on bone metabolism in health and disease. Am J Med. 2001;110(Suppl 3A):43S-5S.
9. Kawaguchi H, Pilbeam CC, Harrison JR, Raisz LG. The role of prostaglandins in the regulation of bone metabolism. Clin Orthop Relat Res. 1995;313:36-46.
10. Raisz LG. Prostaglandins and bone: physiology and pathophysiology. Osteoarthritis Cartilage. 1999;7(4):1-3.
11. Kawaguchi H, Pilbeam CC, Vargas SJ, Morse EE, Lorenzo JA, Raisz LG. Ovariectomy enhances and estrogen replacement inhibits the activity of bone marrow factors that stimulate prostaglandin production in cultured mouse calvariae. J Clin Invest. 1995;96(1):539-48.
12. Jee WS, Ma YF. The in vivo anabolic actions of prostaglandins in bone. Bone. 1997;21(4):297-304.
13. Faye-Petersen OM, Johnson Jr WH, Carlo WA, et al. Prostaglandin E1-induced hyperostosis: clinicopathologic correlations and possible pathogenetic mechanisms. Pediatr Pathol Lab Med. 1996;16(3):489-507.
14. Rashiq S, Logan RF. Role of drugs in fractures of the femoral neck. BMJ. 1986;292(6524):861-3.
15. van Staa TP, Leufkens HG, Cooper C. Use of nonsteroidal anti-inflammatory drugs and risk of fractures. Bone. 2000;27(4):563-8.
16. Thompson DD, Rodan GA. Indomethacin inhibition of tenotomy-induced bone resorption in rats. J Bone Miner Res. 1988;3(4):409-14.
17. Rossini M, Viapiana O, Adami S, et al. Medication use before and after hip fractures: a population based cohort and case-control study. Drugs Aging. 2014;31(7):547-53.
18. Vestergaard P, Hermann P, Jensen JE, Eiken P, Mosekilde L. Effects of paracetamol, non-steroidal anti-inflammatory drugs, acetylsalicylic acid, and opioids on bone mineral density and risk of fracture: results of the Danish Osteoporosis Prevention Study (DOPS). Osteoporos Int. 2012;23(4):1255-65.
19. Carbone LD, Tylaysky FA, Cauley JA, et al. Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity. J Bone Miner Res. 2003;18(10):1795-802.
20. Mann B, Wood E. Confounding in observational studies explained. Open Epidemiol J. 2012;5:18-20.
21. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41-55.
22. Dehejia RH, Wahba S. Propensity score-matching methods for nonexperimental causal studies. Rev Econ Statistics. 2002;84(1):151-61.
23. Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. Validation of the national health insurance research database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf. 2011;20(3):236-42.
24. The Anatomical Therapeutic Chemical (ATC) classification system and the Defined Daily Dose (DDD). http://www.whocc.no/
25. Goodman SN. Toward evidence-based medical statistics. 1: The P value fallacy. Ann Intern Med. 1999;130(12):995-1004.
26. Bauer DC, Orwoll ES, Fox KM, et al. Aspirin and NSAID use in older women: effect on bone mineral density and fracture risk. Study of Osteoporotic Fractures Research Group. J Bone Miner Res. 1996;11(1):29-35.
27. Wilkin TJ, Devendra D. Bone densitometry is not a good predictor of hip fracture. BMJ. 2001;323(7316):795-7.
28. Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ. 1997;315(7115):1096-9.
29. Ekman EF. The role of the orthopaedic surgeon in minimizing mortality and morbidity associated with fragility fractures. J Am Acad Orthop Surg. 2010;18(5):278-85.
30. Kannus P, Parkkari J, Niemi S, et al. Prevention of hip fracture in elderly people with use of a hip protector. N Engl J Med. 2000;343(21):1506-13.
31. McLellan AR, Gallacher SJ, Fraser M, McQuillian C. The fracture liaison service: success of a program for the evaluation and management of patients with osteoporotic fracture. Osteoporos Int. 2003;14(12):1028-34.